People: Biogen Idec Inc (BIIB.O)

Summary

Name	Age	Since	Current Position
William Young	68	2010	Independent Chairman of the Board
George Scangos	64	2010	Chief Executive Officer, Director
Paul Clancy	51	2007	Chief Financial Officer, Executive Vice President - Finance
Kenneth Di Pietro	54	2012	Executive Vice President - Human Resources
Susan Alexander	56	2006	Executive Vice President, Chief Legal Officer and Corporate Secretary
John Cox	50	2010	Executive Vice President - Pharmaceutical Operations and Technology
Steven Holtzman	58	2011	Executive Vice President - Corporate Development
Tony Kingsley	49	2011	Executive Vice President - Global Commercial Operations
Douglas Williams	54	2011	Executive Vice President - Research and Development
Ray Pawlicki	52	2012	Senior Vice President, Chief Information Officer
Gregory Covino	47	2012	Chief Accounting Officer, Vice President - Finance
Alexander Denner	42	2009	Independent Director
Caroline Dorsa	53	2010	Independent Director
Nancy Leaming	65	2008	Independent Director
Richard Mulligan		2009	Independent Director
Robert Pangia		1997	Independent Director
Stelios Papadopoulos	64	2008	Independent Director
Brian Posner	51	2008	Independent Director
Eric Rowinsky	56	2010	Independent Director
Lynn Schenk	68	1995	Independent Director
Stephen Sherwin	64	2010	Independent Director

» Insider Trading

Biographies

Name	Description
William Young	Mr. William D. Young is Independent Chairman of the Board of Biogen Idec Inc., since January 2010. He has also been a venture partner in Clarus Ventures, LLC, a life sciences venture capital firm, since March 2010 and has served as the Executive Chairman of NanoString Technologies, Inc., a provider of molecular diagnostics and a portfolio company of Clarus Ventures, since February 2010. From 1999 to August 2009, Mr. Young served as the Chief Executive Officer of Monogram Biosciences, Inc., a provider of molecular diagnostics, and as its Chairman from 1998 to August 2009. From 1980 to 1999, he held several positions at Genentech, Inc., a life sciences company, and served as its Chief Operating Officer from 1997 to 1999. Prior to joining Genentech, Mr. Young was with Eli Lilly & Co., a pharmaceutical company, for 14 years. He was elected to the National Academy of Engineering in 1993 for his contributions to biotechnology. Mr. Young is a member of the boards of directors of Theravance, Inc. and BioMarin Pharmaceutical Inc., both life sciences companies.
George Scangos	Dr. George A. Scangos Ph.D., is Chief Executive Officer, Director of Biogen Idec Inc. From 1996 to July 2010, Dr. Scangos served as President and Chief Executive Officer of Exelixis, Inc., a drug discovery and development company, where he continues to serve on the board. From 1993 to 1996, Dr. Scangos served as President of Bayer Biotechnology, where he was responsible for research, business development, process development, manufacturing, engineering and quality assurance of Bayer’s biological products. Before joining Bayer in 1987, Dr. Scangos was a Professor of Biology at Johns Hopkins University for six years. Dr. Scangos served as non-executive Chairman of Anadys Pharmaceuticals, Inc., a biopharmaceutical company, from 2005 to July 2010 and was a director of the company from 2003 to July 2010. Dr. Scangos served as the Chair of the California Healthcare Institute in 2010 and was a member of the Board of the Global Alliance for TB Drug Developments until 2010. He is also a member of the Board of Visitors of the University of California, San Francisco School of Pharmacy, and the National Board of Visitors of the University of California, Davis School of Medicine. He is currently an Adjunct Professor of Biology at Johns Hopkins. Dr. Scangos received his B.A. in Biology from Cornell University and Ph.D. in Microbiology from the University of Massachusetts, and was a Jane Coffin Childs Post-Doctoral Fellow at Yale University.
Paul Clancy	Mr. Paul J. Clancy is Chief Financial Officer, Executive Vice President - Finance of Biogen Idec Inc. Mr. Clancy joined Biogen, Inc. in 2001 and has held several senior executive positions, including Vice President of Business Planning, Portfolio Management and U.S. Marketing, and Senior Vice President of Finance with responsibilities for the Treasury, Tax, Investor Relations and Business Planning groups. Prior to that, he spent 13 years at PepsiCo, a food and beverage company, serving in a range of financial and general management positions. Mr. Clancy received his B.S. in Finance from Babson College and M.B.A. from Columbia University.
Kenneth Di Pietro	Mr. Kenneth A. Di Pietro is Executive Vice President - Human Resources of Biogen Idec Inc. Mr. Di Pietro joined Biogen Idec from Lenovo Group, a technology company, where he served as Senior Vice President, Human Resources from 2005 to June 2011. From 2003 to 2005, he served as Corporate Vice President, Human Resources at Microsoft Corporation, a technology company. From 1999 to 2002, Mr. Di Pietro worked as Vice President, Human Resources at Dell Inc., a technology company. Prior to that, he spent 17 years at PepsiCo, a food and beverage company, serving in a range of human resource and general management positions. Mr. Di Pietro received his B.S. in Industrial and Labor Relations from Cornell University.
Susan Alexander	Ms. Susan H. Alexander, Esq., is Executive Vice President, Chief Legal Officer and Corporate Secretary of Biogen Idec Inc. From 2003 to January 2006, Ms. Alexander served as the Senior Vice President, General Counsel and Corporate Secretary of PAREXEL International Corporation, a biopharmaceutical services company. From 2001 to 2003, Ms. Alexander served as General Counsel of IONA Technologies, a software company. From 1995 to 2001, Ms. Alexander served as Counsel at Cabot Corporation, a specialty chemicals and performance materials company. Prior to that, Ms. Alexander was a partner at the law firms of Hinckley, Allen & Snyder and Fine & Ambrogne.
John Cox	Mr. John G. Cox is Executive Vice President - Pharmaceutical Operations and Technology of Biogen Idec Inc. Mr. Cox joined Biogen, Inc. in 2003 and has held several senior executive positions, including Senior Vice President of Technical Operations, Senior Vice President of Global Manufacturing, and Vice President of Manufacturing and General Manager of Biogen Idec’s operations in RTP. Prior to that, Mr. Cox held a number of senior operational roles at Diosynth, a life sciences manufacturing and services company, where he worked in technology transfer, validation and purification. Prior to that, Mr. Cox focused on the same areas at Wyeth Corporation, a life sciences company, from 1993 to 2000. Mr. Cox received his M.B.A. from the University of Michigan and M.S. in Cell Biology from California State University.
Steven Holtzman	Mr. Steven H. Holtzman is Executive Vice President - Corporate Development of Biogen Idec Inc. Prior to that, Mr. Holtzman was a founder of Infinity Pharmaceuticals, Inc., a drug discovery and development company, where he served as Chair of the Board of Directors from company inception in 2001 to November 2012, Executive Chair of the Board of Directors in 2010 and as Chief Executive Officer from 2001 to December 2009. From 1994 to 2001, Mr. Holtzman was Chief Business Officer at Millennium Pharmaceuticals Inc., a biopharmaceutical company. From 1986 to 1994, he was a founder, member of the Board of Directors and Executive Vice President of DNX Corporation, a biotechnology company. From 1996 to 2001, Mr. Holtzman served as presidential appointee to the national Bioethics Advisory Commission. Mr. Holtzman received his B.A. from Michigan State University and B.Phil. graduate degree from Oxford University which he attended as a Rhodes Scholar.
Tony Kingsley	Mr. Tony Kingsley is Executive Vice President - Global Commercial Operations of Biogen Idec Inc. From January 2010 to November 2011, Mr. Kingsley served as Senior Vice President, U.S. Commercial Operations. Prior to that, he served as Senior Vice President and General Manager of the Gynecological Surgical Products business at Hologic, Inc., a provider of diagnostic and surgical products, from October 2007 to November 2009, and as Division President, Diagnostic Products at Cytyc Corp., a provider of diagnostic and medical device products, from July 2006 to October 2007. In those roles, Mr. Kingsley ran commercial, manufacturing and research and development functions. From 1991 to 2006, he was a Partner at McKinsey & Company focusing on the biotechnology, pharmaceutical and medical device industries. Mr. Kingsley received his B.A. in Government from Dartmouth College and M.B.A. from Harvard Graduate School of Business Administration.
Douglas Williams	Dr. Douglas E. Williams, Ph.D., is Executive Vice President - Research and Development of Biogen Idec Inc. Prior to that, Dr. Williams held several senior executive positions at ZymoGenetics Inc., a biopharmaceutical company, including Chief Executive Officer and a director from January 2009 to October 2010, President and Chief Scientific Officer from July 2007 to January 2009, and Executive Vice President, Research and Development and Chief Scientific Officer from 2004 to July 2007. Prior to that, he held leadership positions within the biotechnology industry, including Chief Scientific Officer and Executive Vice President of Research and Development at Seattle Genetics Inc., a biotechnology company, from 2003 to 2004, and Senior Vice President and Washington Site Leader at Amgen Inc., a biotechnology company, in 2002. Dr. Williams also served in a series of scientific and senior leadership positions over a decade at Immunex Corp., a biopharmaceutical company, including Executive Vice President and Chief Technology Officer, Senior Vice President of Discovery Research, Vice President of Research and Development and as a director. Prior to that, Dr. Williams served on the faculty of the Indiana University School of Medicine and the Department of Laboratory Medicine at the Roswell Park Memorial Institute in Buffalo, New York.
Ray Pawlicki	Mr. Ray Pawlicki is Senior Vice President, Chief Information Officer of Biogen Idec Inc. From 2004 to September 2008, Mr. Pawlicki served as the Chief Information Officer of Novartis Pharmaceuticals, a pharmaceutical company. From 2000 to 2004, he served as Vice President and Chief Information Officer for the U.S. affiliate of Novartis Pharmaceuticals. Prior to that, Mr. Pawlicki held several positions of increasing responsibility with PepsiCo, a food and beverage company, and CitiGroup Inc., a financial services company, where he focused on innovative uses of technology to help drive the business. Mr. Pawlicki received his B.S. in Computer Science from Montclair State University.
Gregory Covino	Mr. Gregory F. Covino is Chief Accounting Officer, Vice President - Finance of Biogen Idec Inc. Prior to that, Mr. Covino served at Boston Scientific Corporation, a medical device company, as Vice President, Corporate Analysis and Control since March 2010, having responsibility for the company's internal audit function, and as Vice President, Finance, International from February 2008 to March 2010, having responsibility for the financial activities of the company's international division. Prior to that, Mr. Covino held several finance positions at Hubbell Incorporated, an electrical products company, including Vice President, Chief Accounting Officer and Controller from 2002 to January 2008, Interim Chief Financial Officer from 2004 to 2005, and Director, Corporate Accounting from 1999 to 2002.
Alexander Denner	Dr. Alexander J. Denner, Ph.D. is Independent Director of Biogen Idec Inc., since June 2009. He has been a private investor since November 2011. From 2006 to November 2011, Dr. Denner served as Managing Director of private investment funds affiliated with Carl C. Icahn. From 2005 to May 2006, he served as a portfolio manager specializing in healthcare investments for Viking Global Investors, a private investment fund. Prior to that, Dr. Denner served in a variety of roles at Morgan Stanley, a financial services company, beginning in 1996, including as portfolio manager of healthcare and biotechnology mutual funds. Dr. Denner is the Chairman of Enzon Pharmaceuticals, Inc. and a member of the board of directors of Amylin Pharmaceuticals, Inc., both life sciences companies. During the past five years, Dr. Denner has also served as a director of ADVENTRX Pharmaceuticals, Inc. and ImClone Systems Incorporated, both life sciences companies.
Caroline Dorsa	Ms. Caroline D. Dorsa is Independent Director of Biogen Idec Inc., since January 2010. Ms. Dorsa has been the Executive Vice President and Chief Financial Officer of Public Service Enterprise Group Incorporated, a diversified energy company, since April 2009 and served on that company’s board of directors from 2003 to April 2009. From February 2008 to April 2009, she served as Senior Vice President, Global Human Health, Strategy and Integration at Merck & Co., Inc., a pharmaceutical company. From November 2007 to January 2008, Ms. Dorsa served as Senior Vice President and Chief Financial Officer of Gilead Sciences, Inc., a life sciences company. From February 2007 to November 2007, she served as Senior Vice President and Chief Financial Officer of Avaya, Inc., a telecommunications company. From 1987 to January 2007, Ms. Dorsa held various financial and operational positions at Merck & Co., Inc., including Vice President and Treasurer, Executive Director of U.S. Customer Marketing and Executive Director of U.S. Pricing and Strategic Planning.
Nancy Leaming	Ms. Nancy L. Leaming is Independent Director of Biogen Idec Inc., since January 2008. Ms. Leaming has been an independent consultant since 2005. From 2003 to 2005, she served as the Chief Executive Officer and President of Tufts Health Plan, a provider of healthcare insurance. From 1986 to 2003, Ms. Leaming served in several executive positions at Tufts Health Plan, including President, Chief Operating Officer and Chief Financial Officer. Ms. Leaming is a member of the boards of directors of Hologic, Inc., a provider of diagnostic and surgical products, and Edgewater Technology, Inc., a technology management consulting firm.
Richard Mulligan	Professor Richard C. Mulligan, Ph.D., is Independent Director of Biogen Idec Inc., since June 2009. He has been the Mallinckrodt Professor of Genetics at Harvard Medical School and Director of the Harvard Gene Therapy Initiative since 1996. Prior to that, he was Professor of Molecular Biology at the Massachusetts Institute of Technology, a member of the Whitehead Institute for Biomedical Research, and the Chief Scientific Officer of Somatix Therapy Corporation, a drug discovery and development company that he founded. Dr. Mulligan was named a MacArthur Foundation Fellow in 1981. Dr. Mulligan is Vice Chairman of Enzon Pharmaceuticals, Inc. and a member of the board of directors of Cellectis SA, both life sciences companies. During the past five years, Dr. Mulligan has also served as a director of ImClone Systems Incorporated, a life sciences company.
Robert Pangia	Mr. Robert W. Pangia is Independent Director of Biogen Idec Inc., since September 1997. He has been the Chief Executive Officer of Ivy Sports Medicine, LLC, a medical device company, since July 2011. He has also been a partner in Ivy Capital Partners, LLC, the general partner of Ivy Healthcare Capital, L.P., a private equity fund specializing in healthcare investments, since 2003. From October 2007 to October 2009, he served as the Chief Executive Officer of Highlands Acquisition Corp., a special purpose acquisition company. From 1996 to 2003, Mr. Pangia was self-employed as an investment banker. From 1987 to 1996, he held various senior management positions at PaineWebber, a financial services company, including Executive Vice President and Director of Investment Banking for PaineWebber Incorporated of New York, member of the board of directors of PaineWebber, Inc., Chairman of PaineWebber Properties, Inc., and member of several of PaineWebber’s executive and operating committees. During the past five years, Mr. Pangia has served as a director of McAfee, Inc., a security technology company.
Stelios Papadopoulos	Dr. Stelios Papadopoulos, Ph.D., is Independent Director of Biogen Idec Inc., since July 2008. Dr. Papadopoulos is the Chairman of Exelixis, Inc., a drug discovery and development company that he co-founded in 1994. Previously, he was an investment banker with Cowen & Co., LLC, a financial services company, focusing on the biotechnology and pharmaceutical sectors, from 2000 until his retirement as Vice Chairman in August 2006. Prior to joining Cowen & Co., Dr. Papadopoulos served for 13 years as an investment banker at PaineWebber, Inc., a financial services company, where he was most recently Chairman of PaineWebber Development Corp., a PaineWebber subsidiary focusing on biotechnology. Dr. Papadopoulos is a member of the board of directors of BG Medicine, Inc., a life sciences company. During the past five years, Dr. Papadopoulos has also served as a director of Anadys Pharmaceuticals, Inc., a life sciences company.
Brian Posner	Mr. Brian S. Posner is Independent Director of Biogen Idec Inc., since July 2008. He has been a private investor since March 2008 and is the President of Point Rider Group LLC, a consulting and advisory services firm within the financial services industry. From 2005 to March 2008, Mr. Posner served as the Chief Executive Officer and co-Chief Investment Officer of ClearBridge Advisors LLC, an asset management company and a wholly-owned subsidiary of Legg Mason. Prior to that, Mr. Posner co-founded Hygrove Partners LLC, a private investment fund, in 2000 and served as its Managing Partner for five years. He served as a portfolio manager and an analyst at Fidelity Investments, a financial services company, from 1987 to 1996 and, from 1997 to 1999, at Warburg Pincus Asset Management/Credit Suisse Asset Management where he also served as co-Chief Investment Officer and Director of Research. Mr. Posner is a member of the board of directors of Arch Capital Group Ltd., an insurance company, and BG Medicine, Inc., a life sciences company, and is a member of the board of trustees of AQR Mutual Funds, an investment fund. During the past five years, Mr. Posner has also served as a director of Anadys Pharmaceuticals, Inc., a life sciences company, and as a trustee of RiverPark Funds, an investment fund.
Eric Rowinsky	Dr. Eric K. Rowinsky, M.D., is Independent Director of Biogen Idec Inc., since March 2010. He has been the Head of Research and Development and Chief Medical Officer of Stemline Therapeutics, Inc., a biotechnology company focusing on the discovery and development of therapeutics targeting cancer stem cells, since January 2012. Dr. Rowinsky is also an Adjunct Professor of Medicine at New York University and has been an independent consultant since January 2010. Prior to that, he was the Chief Medical Officer of Primrose Therapeutics, Inc., a start-up biotechnology company focusing on the development of therapeutics for polycystic kidney disease, from August 2010 until its acquisition in September 2011. From 2005 to December 2009, he served as the Chief Medical Officer and Executive Vice President of ImClone Systems Incorporated, a life sciences company. From 1996 to 2004, Dr. Rowinsky held several positions at the Cancer Therapy & Research Center’s Institute for Drug Development, including Director of the Institute and Director of Clinical Research. During that time, he held the SBC Endowed Chair for Early Drug Development and Clinical Professor of Medicine at the University of Texas Health Science Center at San Antonio. From 1988 to 1996, Dr. Rowinsky was an Associate Professor of Oncology at the Johns Hopkins School of Medicine and on the staff of the Johns Hopkins Hospital. Dr. Rowinsky is a member of the boards of directors of Coronado Biosciences, Inc. and Navidea Biopharmaceuticals, Inc., both life sciences companies. During the past five years, Dr. Rowinsky has also served as a director of ADVENTRX Pharmaceuticals, Inc. and Tapestry Pharmaceuticals, Inc., both life sciences companies.
Lynn Schenk	Ms. Lynn Schenk, J.D., is Independent Director of Biogen Idec Inc., since May 1995. She is an attorney and consultant in private practice with public policy and business experience. She is also a trustee of The Scripps Research Institute. From 1999 to 2003, she served as Chief of Staff to the Governor of California, during which time she led the effort to create the Institutes for Science and Innovation at the University of California. From 1993 to 1995, Ms. Schenk was a Member of the United States House of Representatives, representing San Diego, California and served on the House Energy & Commerce Committee with a special emphasis on biotechnology. From 1980 to 1983, she was the California Secretary of Business, Transportation and Housing. Ms. Schenk is a member of the board of directors of Sempra Energy, an energy services and development company.
Stephen Sherwin	Dr. Stephen A. Sherwin, M.D., is Independent Director of Biogen Idec Inc., since March 2010. He has been the Chairman of Ceregene, Inc., a life sciences company that he co-founded, since 2001. From 1990 to October 2009, he served as the Chief Executive Officer of Cell Genesys, Inc., a life sciences company, and was the company’s Chairman from 1994 to October 2009. Prior to that, he held various positions at Genentech, Inc., a life sciences company, most recently as Vice President, Clinical Research. Dr. Sherwin is board certified in internal medicine and medical oncology and currently serves as a Clinical Professor of Medicine at the University of California, San Francisco. Dr. Sherwin is a member of the boards of directors of Neurocrine Biosciences, Inc. and Rigel Pharmaceuticals, Inc., both life sciences companies, and BioSante Pharmaceuticals, Inc., a pharmaceutical company. He is also Chairman Emeritus of the Biotechnology Industry Organization.

Basic Compensation

Name	Fiscal Year Total
William Young	--
George Scangos	11,331,400
Paul Clancy	2,945,650
Kenneth Di Pietro	--
Susan Alexander	2,162,200
John Cox	2,881,180
Steven Holtzman	3,343,620
Tony Kingsley	--
Douglas Williams	3,378,660
Ray Pawlicki	--
Gregory Covino	--
Alexander Denner	--
Caroline Dorsa	--
Nancy Leaming	--
Richard Mulligan	--
Robert Pangia	--
Stelios Papadopoulos	--
Brian Posner	--
Eric Rowinsky	--
Lynn Schenk	--
Stephen Sherwin	--

As Of 30 Dec 2011

Options Compensation

Name	Options	Value
William Young	0	0
George Scangos	1,151,530	14,729,400
Paul Clancy	43,516	1,201,850
Kenneth Di Pietro	0	0
Susan Alexander	0	0
John Cox	52,499	1,342,680
Steven Holtzman	0	0
Tony Kingsley	0	0
Douglas Williams	0	0
Ray Pawlicki	0	0
Gregory Covino	0	0
Alexander Denner	0	0
Caroline Dorsa	0	0
Nancy Leaming	0	0
Richard Mulligan	0	0
Robert Pangia	0	0
Stelios Papadopoulos	0	0
Brian Posner	0	0
Eric Rowinsky	0	0
Lynn Schenk	0	0
Stephen Sherwin	0	0

Insider Trading

Name	Shares Traded	Price
PAWLICKI RAYMOND	866	$218.85
COX JOHN G	866	$218.85
SCANGOS GEORGE A	1,598	$215.39
COVINO GREGORY F	114	$214.33
COVINO GREGORY F	347	$0.00
CLANCY PAUL J	1,968	$222.57
CLANCY PAUL J	5,380	$224.34
CLANCY PAUL J	900	$226.01
CLANCY PAUL J	6,241	$225.40
CLANCY PAUL J	9,123	$219.71
SCANGOS GEORGE A	1,598	$193.66
SHERWIN STEPHEN A	1,500	$176.88
MULLIGAN RICHARD C	2,900	$176.88
POSNER BRIAN S	4,500	$174.81
MULLIGAN RICHARD C	2,980	$174.75
MULLIGAN RICHARD C	5,000	$175.75
PAPADOPOULOS STELIOS B	5,975	$53.43
PAPADOPOULOS STELIOS B	31,034	$172.08
PAPADOPOULOS STELIOS B	3,966	$172.72
PAPADOPOULOS STELIOS B	5,700	$172.45
PAPADOPOULOS STELIOS B	5,700	$59.17
PAPADOPOULOS STELIOS B	5,975	$172.67
PAPADOPOULOS STELIOS B	35,000	$59.17
PAWLICKI RAYMOND	630	$168.70
SCANGOS GEORGE A	1,598	$165.30

» Full list on Insider Trading

People: Biogen Idec Inc (BIIB.O)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: